SOURCE-LINKED STUDY SUMMARY
A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity.
Abstract summarizedQuality not appraised
- What was studied
- Randomized double-blind trial of daily liraglutide 3.0 mg versus placebo, both with lifestyle therapy, for 56 weeks followed by 26 weeks off treatment.
- Who / model studied
- Adolescents aged 12 to under 18 with obesity and poor response to lifestyle therapy, with 125 assigned liraglutide and 126 assigned placebo.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- At week 56, the estimated difference in BMI standard-deviation score was -0.22 in favor of liraglutide. At least 5% BMI reduction occurred in 43.3% versus 18.7%. Gastrointestinal events occurred in 64.8% versus 36.5%, and discontinuations in 10.4% versus 0. BMI score increased more after liraglutide was stopped.
- Limitations & context
- The study involved adolescents who had not responded adequately to lifestyle therapy, so results do not establish outcomes in other populations. Follow-up after treatment lasted 26 weeks. Novo Nordisk funded the trial.
Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1056/nejmoa1916038